Product Information
GLEEVEC 400 MG TABLET is a brand product labeled by Novartis Pharmaceuticals Corporation, priced at $328.0342 per EA under NDC 00078064930. Its NADAC has been published 414 times since Feb 11, 2015.
FDA first approved this application on Apr 18, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the imatinib mesylate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
400 mg/1
Manufacturer
Novartis Pharmaceuticals CorporationNDC
00078064930
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/18/2024
Active Ingredients
IMATINIB MESYLATEApproval Type
New Drug (NDA)
FDA Application
NDA021588FDA Approved
4/18/2003
TE Code
AB
On Market Since
12/23/2014
Pharmacological Classes
Price Statistics
The NADAC for GLEEVEC 400 MG TABLET has been published 414 times since Feb 11, 2015, and over the history we have for it it has risen 9.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $328.0342 per EA |
|---|---|
| All-time high | $329.4851 (May 15, 2024) |
| All-time low | $298.7430 (Mar 18, 2015) |
| 52-week high | $328.0342 |
| 52-week low | $328.0342 |
| Median price | $328.0342 |
| Average price | $325.3913 |
| Largest weekly change | +9.9% (Jul 15, 2015) |
| Weeks tracked | 414 |
| Tracking since | Feb 11, 2015 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
0.0%
3Y
-0.1%
5Y
-0.1%
All
+9.6%
Last surveyed Sep 10, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 99% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of GLEEVEC 400 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for GLEEVEC 400 MG TABLET, manufactured by Novartis Pharmaceuticals Corporation, is $328.0342 per EA (NDC 00078064930), effective Sep 10, 2025.
How has the price of GLEEVEC 400 MG TABLET changed over time?
Over the history we have for it, the NADAC for GLEEVEC 400 MG TABLET has risen 9.6%. It has been tracked across 414 weekly CMS publications since Feb 11, 2015.
What are the highest and lowest recorded NADAC prices for GLEEVEC 400 MG TABLET?
Since Feb 11, 2015, the NADAC for GLEEVEC 400 MG TABLET has ranged from a low of $298.7430 (Mar 18, 2015) to a high of $329.4851 (May 15, 2024), with a median of $328.0342 per EA.
Are there cheaper alternatives to GLEEVEC 400 MG TABLET?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, IMATINIB MESYLATE 400 MG TAB, is $2.0356 per EA — about 99% below GLEEVEC 400 MG TABLET.
Who manufactures GLEEVEC 400 MG TABLET?
GLEEVEC 400 MG TABLET (NDC 00078064930) is labeled by Novartis Pharmaceuticals Corporation, and CMS classifies it as a brand product.